Fresenius And Formycon File Ustekinumab In US

Firms Submit BLA For FYB202 Stelara Biosimilar To FDA; Launch Anticipated In April 2025

 
• By Dave Wallace

Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.

Sign outside of FDA's headquarters in White Oak, MD
Fresenius Kabi and Formycon have submitted their filing to the FDA • Source: Alamy

More from Biosimilars

More from Products